While numerous studies have demonstrated that increased TILs are associated with improved outcomes in patients with triple-negative and Her2-positive breast cancer, no significant prognostic value has been found for TILs in ER+ Her2- disease [45], particularly in patients who do not receive chemotherapy [46]. The gene discussed is ERBB2; the disease is breast cancer.